Eli Lilly Makes $16 BILLION on Tirzepatide in Just 90 Days! DOWNSIZED NEWS
The Downsized — Eli Lilly Makes $16 BILLION on Tirzepatide in Just 90 Days! DOWNSIZED NEWS
Channel: DOWNSIZED · Our label: Patient-experience channel — GLP-1 journey, daily · Source: youtube.com/watch?v=Eha7Ya1KV1c
What this video covers
Eli Lilly’s triple hormone medication went head-to-head with Ozempic and more than doubled the weight loss. A motion sickness pill cut GLP-1 vomiting in a phase three trial and a federal judge has ruled in the advertising fight between Lilly and Novo Nordisk and nearly three out of four GLP-1 patients say they now wear a different size. It’s Monday, November 2nd, 2026 and my name is Christopher Durham. Christopher and I celebrated 3 years on GLP-1 medications last month.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- A motion sickness pill cut GLP-1 vomiting in a phase three trial and a federal judge has ruled in the advertising fight between Lilly and Novo Nordisk and nearly three out of four GLP-1 patients say they now wear a different size.
- Nothing we share here is medical advice, so always work with your health care professional on decisions about your health.
- They ran a test and it turns out » Retatrutide » it’s twice as effective as Ozempic at weight loss.
- A study in JAMA Network Open of more than 125,000 adults with overweight or obesity found that more than half stopped their GLP-1 within a year, and gastrointestinal side effects were linked to stopping.
- It’s based on a July survey by the healthcare technology company Tevra of 374 providers who prescribe or manage GLP-1 treatment.
- Viking is also testing VK3019, an experimental amylin drug, in an early safety study due to finish by year end with a 4-week study plan for early 2027.
Read next
- GLP-1 class — more videos
- Semaglutide — more videos
- Tirzepatide — more videos
- Retatrutide — more videos
- All videos from this channel
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.